Novartis ($NVS) was last year's biggest R&D spender in the pharma industry. Now, the company is warning U.K. officials that, unless they change their ways, Novartis will be spending less and less of its research billions in that country. Report
| Wednesday, June 10th | 1pm ET / 10am PT | Presented by: Rho
Interest in using electronic patient reported outcomes (ePRO) on smart devices is on the rise. In this webinar, Emily Cantrell and Becky Baggett will share lessons learned working on a large phase 3 pain study that utilizes ePRO on tablet devices. Register Now!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!